Canadian Securities ExchangeThe Daily Bell

GeneTether Therapeutics (CSE:GTTX) w/ Roland Boivin & Geoffrey Sargent

New Canadian Stocks

May 9, 2022Newly Listed on the CSE

(CSE:GTTX)

About This Video

GeneTether Therapeutics is a public company listed on the Canadian Securities Exchange stock market under the symbol GTTX.

GeneTether Therapeutics is an innovative genetic medicines company focused on creating best-in-class gene editing therapies based on our proprietary GeneTether platform. Our platform is designed to increase the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs. We use a proprietary method to “tether” donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage.

Learn more about GeneTether Therapeutics at https://www.thecse.com/en/listings/life-sciences/genetether-therapeutics-inc.

Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe

STAY CONNECTED WITH THE CSE

=============================

- NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe

- PODCAST: https://blog.thecse.com/cse-podcasts/

- INSTAGRAM: https://www.instagram.com/canadianexchange/

- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange

- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/

- TWITTER: https://twitter.com/CSE_News

- BLOG: https://blog.thecse.com/

- WEBSITE: https://thecse.com/

- MAGAZINE: https://issuu.com/thecse/docs

Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.

congratulations on being newly listed on the cse thank you to everyone for tuning back into another newly listed on the csc clip today we are talking to gene tether therapeutics inc this is a company that has listed on the csc late march trades under the symbol gttx and representing gene tether we've got roland boyvan he's the ceo of the company along with mr jeffrey sargent who is the chief scientific officer for

the company gentlemen thank you so much for taking the time to join us today how are you very good thank you and thank you thanks excellent well this is you know typically we have one person from the company but but this is a sort of an interesting play it called gene tether we want to make sure that our viewers can fully understand what this company is about so roland why don't we

begin by talking a little bit about what the company does and what the vision here is yeah sounds good yeah and i'll start at a high level and as you can imagine jeff will be the one who will be digging a lot deeper on the science side of it but really gene tethers an innovative genetic medicine company focusing on gene editing efficiency so what we have is a highly disruptive

platform that drives efficiency in gene correction and gene complementation strategies and again jeff will expand on that in a minute just want to let you know that we've just closed the ipo as you said just listed recently close an ipo 4.5 million dollars pleased with that in these pretty difficult market conditions on that though i'll let jeff explain a little bit more on the science because it's something we he needs to give a bit

of background before we start talking about what we have as a company so jeff i'll leave it up to you are you sure thanks roland yeah to give you a little bit of context i mean one of the things i'm going to say start out from the top is kind of a mantra that we have and that's proximity matters and i'll explain why that's important in just a second but first i want to give

you a little bit of background and you know when we talk about gene editing and crispr and kaz and all these buzzwords that are out there now how do you do that what does that mean and part of the process is that if you're going to fix a mutation in the dna say for example sickle cell if you wanted to correct the sickle cell mutation the first thing you have to do is damage the

dna and the second thing is you provide a second piece of dna to fix that damage okay so that's that's kind of the concept the conceptual process now with crispr chaos what you do this is a nuclease that you can program you can give it an address right okay so if you wanted to fix sickle cell mutation again you would give the crispr cast protein the address of

exon one and the beta globin gene it would go there in the cell you would introduce in the cell and go there and cut the dna okay so the crispr cast part of it is to make site-specific dna strand breaks okay now if you wanted to fix mutation what you do is you have that second piece of dna and it has information to fix the mutation but the way the experiment is usually

done is that that second piece of dna used to fix is just floating around in the cell and what we have done when i say proximity matters is that we figured out how to attach that piece of dna repair used to repair those dna strand breaks to the cas9 so it's physically near the dna strand breaks when you've got to fix them okay and so that's that's the conceptual

idea now the part of the problem is is if that repair dna is not nearby and you make dna double strand breaks and bad things happen you can get deletions where you lose dna sequence you can add in extra pieces of dna sequence so by adding this repair template nearby you help to try to prevent that very interesting this is you know something that's that's a sort of a new

thing to me anyway so i'm i'm very curious to actually talk to the both of you a little bit more and find out more about the company so what was the strategy behind taking this public yeah well first off just some quick background on how gene tether was created it was basically co-founded by by jeff who is here with me today but also with it was also co-founded by

dr bill garner who is the founder of egb ventures so the model that egb venture has for its portfolio companies typically is they take the companies public at an earlier stage it's not for an exit it's a lot more so and it's something that they call public venture capital and so in addition to obviously having more flexibility in the funding alternatives when you're publicly listed it's also a question of taking companies

into the public markets at a very modest valuation and actually building through successful execution of the solid plan which would then you know translate into a share price and market cap so it really gives an opportunity to participants in the ipo to really be part of the upside and that's the main reason for it i want to talk a little bit about you know not only the both of your

background and how you got into this space but any of your key team members that you've brought along to move this technology forward so why don't we start with jeffrey on this one talk to us a little bit about how you got into this space sure well let me tell you a little about myself first i mean i have a phd in biochemistry and biophysics and you know one of the things i like to

tell people is that i've been working in gene editing since 1987 before gene editing was a thing okay but you know the way the way i got into it was that you know when you get when you're in graduate school you have to review papers in front of your laboratory and one of the last things i did was to review this paper from these two scientists raju kukulapati and oliver

smithey's it was the first paper to show you could do gene editing in animal cells i mean before that it was just thought to be too hard so this is a real watershed moment and i realized then that if we're ever going to have the capability to treat genetic disease inherited diseases then this technology has to be developed and improved and so i literally in 1987 set out to make my career kind of

centered around doing that so i started some of this work at a when i was a in england at a place called the imperial cancer research fund and then in in i moved from there to baylor college of medicine in houston where i really was focused on understanding the machine the cellular machinery that is used to repair dna double strand breaks okay because it was clear then that you

know if you can make a dna double stranded break in a particular place then you can increase the gene editing efficiency massively and so some of the work actually at better college of medicine inspired our development of the platform you know 20 20 years later and so from baylor i moved out to the san francisco bay area in 1998 to work in biotech it turns out i have

some i can stand the tolerance the risk in biotech startup so and i stayed out here working in biotech and academia in gene editing when i can as as the opportunity presented to me but in 2017 we were doing some gene editing experiments where we were trying to fix sickle cell and cystic fibrosis mutations and i could see we're making dna strand breaks in like five percent

of the cells but our gene editing efficiencies were 10 000 times lower and i started thinking what what's the disconnect here i knew from my work at baylor it shouldn't be this bad and that inspired us to be able to engineer this this modification of cas9 to bring in our dna strand templates near the dna strand break when it's being made i'd also like to introduce peter sampson dr peter sampson peter's a

medicinal chemist by training he got his phd in organic chemistry from university of waterloo but peter brings in that whole translational aspect of biotech he has been in the pre-ind space and so peter brings in that aspect that part of the his experience he's also worked in even though he's an organic chemist he's worked in genomics and epigenetics so he brings in that side of knowledge of life

sciences and he's also had a lot of experience in intellectual property management so peter's a great addition to our team to help balance things out and complement some of the expertise that we need thank you for that jeffrey it's really fascinating stuff roland i'm gonna i'm gonna pass you the virtual microphone tell us a little bit about yourself sure i joined in this last october as ceo of the company and a bit

of background on myself i spent almost 20 years at 3m and that's where i really learned to run a business whether it was sales marketing business development i actually ran the consumer division there for several years and when i left i was an executive of the company reporting directly to the president and then comes into the second stage of what i my experience basically as cfo of

public holistic companies several of them the last one being the latest one being mid-axis pharmaceuticals during my time as cfo raised over 150 million dollars in financings all kinds of different financings and also led license and m a deals of over 200 million as well so that's my background and i'd like to spend a couple of minutes on the chair by side of our scientific ad board which is dr khalid

miyote so cole deep is as i said the new chair or sab he's a canadian but he's based in the boston area he's got a phd in molecular genetics entrepreneur in residence at facet in toronto and at nih in maryland he started as a research scientist advisor and then moved into different roles that j jnj and eli lilly where he was more focused on new ventures external collaborations

external innovations creating new codes etc he actually led lilly's acquisition of prevail therapeutics over about a year and a half ago his expertise is critical to us because in this space there's a lot of collaborations and a lot of collaboration opportunities we've already had some discussions we are in discussions with the other genetic medicine companies to talk about collaboration and khaldhi's been a key a person involved in that as well so he's

already bringing a lot of value and finally quick word on our cfo jean jan jean is a cpa ca over 12 years of experience in finance accounting public and private companies in the life science sector she's been a great addition to her team and she's doing a great job these are the main people on our team right now and you thank you for that roland you mentioned

collaboration but i imagine that this is a space that's also got a lot of competition i'm not sure if you have how much competition you have but i want to talk a little bit about something that might differentiate not only your team but also your your your vision from some of the peers that might be in this space and feel free to jump in both of them

yeah well i'll start just at a very high level i mean there are several companies out there focusing on gene editing now our focus is very specific on gene editing efficiency for gene correction complementation one thing that we're really excited about is the fact that our platform is modular and so that means that we we believe it works across most gene editing systems regardless of disease or organ and so

that's at a very high level now and more on the science side of it jeff i'll let you kind of jump in here sure i mean the essential themed what we want to do is increase this what i would call gene correction you present to some to a physician with a genetic disease we want to be able to fix that mutation okay and so in order to do that that's actually quite

difficult thing to do what our technology does and what we've done in our proof of concept to show that we can increase gene editing efficiency increase the ability to fix mutations at least seven-fold and so that's really kind of the core drive what we're trying to do is increase this gene editing efficiency so we can take it to a higher level and be able to use it ultimately in the

clinic for for treating genetic disease and this is you know if you can only fix a mutation in a few cells you can't necessarily cure the disease so that's that's really where we're driving towards all right and the the other aspect to this is that we believe our our technology is modular so we can use this with other crispr cast systems as they're discovered and this is important

because some of them have better efficiencies at being able to cut dna and target some of them are just smaller and that's really important when you start thinking about how you're going to put all this into the cell thank you for that jeffrey now you know obviously as you begin treating this is sort of the starting point you're just beginning your journey in the public capital markets are there any milestones

that you are able to talk about that our viewers can look out for in the coming months well i'm going to start just the you know obviously jeff will will expand on the r d milestones per se but there are other milestones too as well to look forward to i mean i didn't spend a lot of time talking about our ip but rip is very strong it's wholly owned it's got

broad claims and it covers the different nucleases as jeff mentioned a little earlier we've got a patent issued in australia and we also received notice of allowance from the uspto recently so plus seven others that are pending so potential milestones coming up in in the ips aspect of it also as i was saying before collaborations i mean we we are collaborating right now with a few

collaborators like z clinics and uc davis for instance and there's going to be more and more of those collaborations but also potentially collaborations with much larger genetic medicine companies which is common in in this industry so those are the non-r d specific ones i'll let jeff expand a little bit on the r d ones sure when whenever you have a a platform like we have one of the things that you

want to do is show its universality that it it can be used to treat genetic disease in a number of different cells a number of different genes and a number of different tissues and so our really near-term milestones are to simply to do that to demonstrate that we are able to make gene corrections in different genes and different cell lines and we have some particular targets that we're interested in one is

for example an inherited disease kidney disease in a protein called umod or uromodulin and so that's gonna be one of the targets that we're gonna be working with now you know when i say genes tissues organs this is also applicable to plants and animals and so we have some discussions that are ongoing with a company to work in in the plant system and milan mentioned that we

already have some ongoing collaborations in with z clinics and uc davis where with uc davis we're focused on looking at being able to make gene edits in large animals so this is a technology that's broadly applicable across a lot of different spaces that we think we can play in i would encourage all of our viewers to definitely go to your website and read up a little bit more on this

company you know obviously read up on the team their background and expertise roland where can our viewers go to sign up for your press releases to read up more on this stuff and educate themselves on what your company is doing yeah our website basically genether.com is is the place where all that can be done and we have some information on it we're going to keep updating it but it's

a great place to start for any of your few years well said now on behalf of our team at the canadian securities exchange we wish you and your team nothing but success as you move forward and you're building this out i look forward to hosting both of you on again in the next little while so we can provide our viewers with an update on your successes but again i want to thank

both of you for taking the time to join us today to our viewers you've been listening to both roland boyvan he's the ceo as well as mr jeffrey sargent who is the chief scientific officer of gene tether therapeutics inc trades on the csc under the symbol gttx and again i want to thank you all for tuning back in i'm a neil mall i represent the canadian securities

exchange gentlemen thank you so much for taking the time today thanks for having us thanks a lot neil cheers

More Newly Listed on the CSE

See them all

Tiger Financial (CSE:BANQ)From Cash to DigitalOct 27, 2026
Caldwell-Lazard CorePlus Infrastructure Fund (CSE:CPIF)Sep 14, 2026
SECUR3D Holdings (CSE:SRD)AI-Powered Brand ProtectionSep 8, 2026
Secur3D Holdings (CSE:SRD)AI-Powered Brand & IP ProtectionAug 20, 2026